

NCT03472508 comparison:

Summary:
CHIA has 16 criteria while your personal folder has 16 criteria
Total found criteria: 15/16
Total not Found: 1/16
Total Extra: 5
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ (2)A diagnosis or previous diagnosis of essential  │ （2）A diagnosis or previous diagnosis of          │
│ hypertension, including anyone currently taking    │ essential hypertension, including anyone currently │
│ antihypertensive drugs; or for those who have not  │ taking antihypertensive drugs; or for those who    │
│ taken antihypertensive drugs within the last 2     │ have not taken antihypertensive drugs within the   │
│ weeks, two consecutive examinations were conducted │ last 2 weeks, two consecutive examinations were    │
│ at least one day apart, and both sitting blood     │ conducted at least one day apart, and both sitting │
│ pressure (mean value of 3 measurements) met the    │ blood pressure (mean value of 3 measurements) met  │
│ following criteria: diastolic blood pressure (DBP) │ the following criteria: diastolic blood pressure   │
│ =90 mmHg or systolic blood pressure (SBP) =140     │ (DBP) ≥90 mmHg or systolic blood pressure (SBP)    │
│ mmHg (the second blood pressure was measured at    │ ≥140 mmHg (the second blood pressure was measured  │
│ V1)                                                │ at V1)                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (3)If a study participant is a woman of            │ （3）If a study participant is a woman of          │
│ childbearing age, she agrees to use a reliable     │ childbearing age, she agrees to use a reliable     │
│ contraceptive method during the trial              │ contraceptive method during the trial              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (4)Voluntarily participates and has signed an      │ （4）Voluntarily participates and has signed an    │
│ informed consent form                              │ informed consent form                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (1)Completed MTHFR C677T gene polymorphism         │ （1）Completed MTHFR C677T gene polymorphism       │
│ detection in run-in period or MTHFR C677T genotype │ detection in run-in period or MTHFR C677T genotype │
│ already known in advance                           │ already known in advance                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (2)Exhibited good tolerance to enalapril and good  │ （2）Exhibited good tolerance to enalapril and     │
│ overall medication compliance (>80%) in run-in     │ good overall medication compliance (\>80%) in run- │
│ period or previously exhibited good tolerance and  │ in period or previously exhibited good tolerance   │
│ adherence to ACEI drugs in previous medication     │ and adherence to ACEI drugs in previous medication │
│ history                                            │ history                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (3)Voluntarily continues to participate in this    │ （3）Voluntarily continues to participate in this  │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (1)Women who are pregnant and/or lactating; or     │ （1）Women who are pregnant and/or lactating; or   │
│ women who intend to conceive within a year         │ women who intend to conceive within a year         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (2)History of allergies to enalapril, folic acid   │ （2）History of allergies to enalapril, folic acid │
│ or other components of the compound drug           │ or other components of the compound drug           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (3)History of adverse reactions or intolerance to  │ （3）History of adverse reactions or intolerance   │
│ enalapril or other ACE inhibitors, or drugs or     │ to enalapril or other ACE inhibitors, or drugs or  │
│ supplements containing folic acid                  │ supplements containing folic acid                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (4)Diagnosis or suspicion of secondary             │ （4）Diagnosis or suspicion of secondary           │
│ hypertension                                       │ hypertension                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (5)Known serious medical conditions, including:    │ （5）Known serious medical conditions, including:  │
│ Cardiovascular: patients with clinically diagnosed │ Cardiovascular: patients with clinically diagnosed │
│ cardiac dysfunction (NYHA class III and above),    │ cardiac dysfunction (NYHA class III and above),    │
│ hypertrophic obstructive cardiomyopathy,           │ hypertrophic obstructive cardiomyopathy,           │
│ clinically significant valvular heart disease,     │ clinically significant valvular heart disease,     │
│ acute coronary syndrome within the last 3 months,  │ acute coronary syndrome within the last 3 months,  │
│ or percutaneous coronary intervention (PCI), or    │ or percutaneous coronary intervention (PCI), or    │
│ coronary artery bypass graft (CABG); or abnormal   │ coronary artery bypass graft (CABG); or abnormal   │
│ pre-enrollment ECG test results with clinically    │ pre-enrollment ECG test results with clinically    │
│ significant arrhythmias (atrial flutter, atrial    │ significant arrhythmias (atrial flutter, atrial    │
│ fibrillation, grade II-III atrioventricular block, │ fibrillation, grade II-III atrioventricular block, │
│ etc.); Digestive: a previous diagnosis of various  │ etc.); Digestive: a previous diagnosis of various  │
│ types of viral hepatitis that are still in the     │ types of viral hepatitis that are still in the     │
│ active phase; abnormal pre-enrollment liver        │ active phase; abnormal pre-enrollment liver        │
│ function test results (ALT, AST, GGT, TBIL, or     │ function test results (ALT, AST, GGT, TBIL, or     │
│ DBIL 3 times higher than normal, ALB = 30g/L);     │ DBIL 3 times higher than normal, ALB ≤ 30g/L);     │
│ gastrectomy and/or gastrojejunostomy;              │ gastrectomy and/or gastrojejunostomy;              │
│ gastrointestinal dysfunction; Urinary: pre-        │ gastrointestinal dysfunction; Urinary: pre-        │
│ enrollment serum creatinine greater than           │ enrollment serum creatinine greater than           │
│ 200umol/L; clinical diagnosis of renal artery      │ 200μmol/L; clinical diagnosis of renal artery      │
│ stenosis, isolated kidney, kidney transplantation  │ stenosis, isolated kidney, kidney transplantation  │
│ and/or other diseases; Endocrine: type 1 diabetes  │ and/or other diseases; Endocrine: type 1 diabetes  │
│ or uncontrolled type 2 diabetes (fasting blood     │ or uncontrolled type 2 diabetes (fasting blood     │
│ glucose above 11.1 mmol/L at pre-enrollment);      │ glucose above 11.1 mmol/L at pre-enrollment);      │
│ previous diagnosis of hyperthyroidism and failure  │ previous diagnosis of hyperthyroidism and failure  │
│ to correct; Respiratory: pulmonary heart disease;  │ to correct; Respiratory: pulmonary heart disease;  │
│ chronic obstructive pulmonary disease;             │ chronic obstructive pulmonary disease;             │
│ Neuropsychiatric: recent transient ischemic attack │ Neuropsychiatric: recent transient ischemic attack │
│ or stroke (within the last 3 months); peripheral   │ or stroke (within the last 3 months); peripheral   │
│ or severe autonomic dysfunction; mental or nervous │ or severe autonomic dysfunction; mental or nervous │
│ system dysfunction, inability to express desire;   │ system dysfunction, inability to express desire;   │
│ known drug or alcohol dependence; Malignancy,      │ known drug or alcohol dependence; Malignancy,      │
│ malnutrition, hematopoietic disorders and other    │ malnutrition, hematopoietic disorders and other    │
│ serious diseases                                   │ serious diseases                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (6)Significant signs of abnormalities as seen in   │ （6）Significant signs of abnormalities as seen in │
│ laboratory tests or physical characteristics,      │ laboratory tests or physical characteristics,      │
│ which, at the discretion of the investigators,     │ which, at the discretion of the investigators,     │
│ indicates that the patient is experiencing a       │ indicates that the patient is experiencing a       │
│ serious illness or, may affect the observation and │ serious illness or, may affect the observation and │
│ evaluation of the drug's efficacy or adverse       │ evaluation of the drug's efficacy or adverse       │
│ events, or renders the patient unsuitable for      │ events, or renders the patient unsuitable for      │
│ participating in this study                        │ participating in this study                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (7)Patients currently taking folate, B12, or B6,   │ （7）Patients currently taking folate, B12, or B6, │
│ or any compounds containing them, who express an   │ or any compounds containing them, who express an   │
│ inability or a refusal to stop usage               │ inability or a refusal to stop usage               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (8)Regular usage of folic acid supplements or      │ （8）Regular usage of folic acid supplements or    │
│ compounds containing folic acid in the past 3      │ compounds containing folic acid in the past 3      │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ (9)Participation in a clinical trial for a drug    │ （9）Participation in a clinical trial for a drug  │
│ that has not yet been officially approved for      │ that has not yet been officially approved for      │
│ marketing within one month prior to the first      │ marketing within one month prior to the first      │
│ visit                                              │ visit                                              │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal   │
╞═══════════════════════════════════════╡
│ (1)= 45 years old                     │
╘═══════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════╡
│ Inclusion Criteria for Double-Blind Treatment Period                                 │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 45 Years                                                    │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ for run-in period                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ （1）≥ 45 years old                                                                  │
├──────────────────────────────────────────────────────────────────────────────────────┤
│ Participants meeting any of the following criteria may not participate in this study │
╘══════════════════════════════════════════════════════════════════════════════════════╛